Pipelines
| Product | Modality | Indication | Target | Candidate | Preclin | Phase I | Grant |
| AMB302 | ADC | UC, HNSCC | FGFR3 |  |
|||
| AMB303 | ADC | Solid tumors | |||||
| AMB304 | ADC | Solid tumors | |||||
| AMB201 | Bs-ADC | Solid tumors | |||||
| AMB202 | Bs-ADC | Solid tumors | |||||
| AMB001 | mAb | Atopic dermatitis & dementia |
CD200R1 | |
|||
| AMB018 | ADC/ISAC | Solid tumors | |
Platforms
| Product | Tech | Indication | Class | Development | Optimization | Application |
| AMB401 | Payload | Solid tumors | Duocarmycin | |||
| AMB402 | Payload | Solid tumors | Camptothecin | |||
| AMB008 | BBB penetration | Brain diseases |
| Product | Modality | Development Status |
|---|---|---|
| AMB302 | ADC | Clinical |
| Indication | Target | |
| Urothelial carcinoma, HNSCC | FGFR3 | |
Grant
AIMEDBIO’s proprietary FGFR3-targeting antibody conjugated with GeneQuantum’s topoisomerase I inhibitor to target FGFR3 overexpressing or altered solid tumors.
| Product | Modality | Development Status |
|---|---|---|
| AMB303 | ADC | Preclinical |
| Indication | Target | |
| Solid tumors | Undisclosed | |
| Product | Modality | Development Status |
|---|---|---|
| AMB304 | ADC | Preclinical |
| Indication | Target | |
| Solid tumors | Undisclosed | |
| Product | Modality | Development Status |
|---|---|---|
| AMB201 | Bs-ADC | Candidate Selection |
| Indication | Target | |
| Solid tumors | Undisclosed | |
| Product | Modality | Development Status |
|---|---|---|
| AMB202 | Bs-ADC | Candidate Selection |
| Indication | Target | |
| Solid tumors | Undisclosed | |
| Product | Modality | Development Status |
|---|---|---|
| AMB001 | mAb | Preclinical |
| Indication | Target | |
| Atopic dermatitis, dementia | CD200R1 | |
Grant
An anti-CD200R1 monoclonal antibody which regulates immune checkpoint through agonistic effect.
| Product | Modality | Development Status |
|---|---|---|
| AMB018 | BsAb | Candidate selection |
| Indication | Target | |
| Solid tumor | Undisclosed | |
Grant
Platforms
| Product | Modality | Indication |
|---|---|---|
| AMB401 | Payload | Optimization |
| Indication | Class | |
| Solid tumors | Duocarmycin | |
| Product | Modality | Indication |
|---|---|---|
| AMB402 | Payload | Optimization |
| Indication | Class | |
| Solid tumors | Camptothecin | |
| Product | Modality | Indication |
|---|---|---|
| AMB008 | BBB penetration | Development |
| Indication | ||
| Solid tumors | ||
